QNCX - Quince Therapeutics, Inc.
Quince Therapeutics, Inc. Logo

QNCX - Quince Therapeutics, Inc.

https://www.quincetx.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - APA ( NASDAQ:APA ) , Lionsgate Studios ( NYSE:LION )
Benzinga • 1 month, 1 week ago • score: 0.41
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo analyst Omar Mejias initiated coverage on Lionsgate Studios Corp.
Bullish
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Six Flags Entertainment ( NYSE:FUN )
Benzinga • 10 months, 2 weeks ago • score: 0.15
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies analyst Young Li initiated coverage on RxSight, Inc. RXST with a Buy rating and announced a price ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. The company is headquartered in South San Francisco, California.

52W High
$2.45
52W Low
$0.68
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.00
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
1.44
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
7.37
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
11.12%
Institutions (25–75% balanced)
23.10%
Shares Outstanding
53,714,000
Float
44,783,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-1.10
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-1.67%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0185
Previous
-0.0202
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025